<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985010</url>
  </required_header>
  <id_info>
    <org_study_id>HGDrDFF-Mn2008</org_study_id>
    <nct_id>NCT00985010</nct_id>
  </id_info>
  <brief_title>Manganese in Women With Encephalopathy</brief_title>
  <official_title>Manganese, Possible Factor of Higher Mortality in Women With Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materno-Perinatal Hospital of the State of Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General &quot;Dr. Darío Fernández Fierro&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurology and Neurosurgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Materno-Perinatal Hospital of the State of Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

      Report manganese serum levels and mortality in encephalopathic patients.

      Patients and participants:

      Consecutive patients aged &gt; 18 years, with hepatic encephalopathy and informed consent signed
      by their families.

      Interventions:

      Patients' clinical characteristics as well as biochemical tests of renal function,
      hemoglobin, glucose and albumin levels were obtained as well as a blood sample to analyze
      manganese levels with a graphite furnace atomic absorption spectrometer.

      Hypothesis:

      There is a difference in the manganese levels between male and female patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The authors finished their jobs in the hospitals where the study was begun.
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Evolution</measure>
    <time_frame>six months</time_frame>
    <description>Number of participants who died versus those who remained alive after 6 months of follow up since the first entrance at the Emergency Room</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Manganese Levels</measure>
    <time_frame>Up to six months we followed the recruited patients to determine who were still alive</time_frame>
    <description>From encephalopathic patients, we took individual blood samples, analyzed in the biochemistry laboratory at the National Institute of Neurology and Neurosurgery, Mexico, City, with a graphite furnace atomic absorption spectrometer, according to the technique reported by Pleban.</description>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients aged &gt; 18 years, with hepatic encephalopathy and informed consent
        signed by their families.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients aged &gt; 18 years

          -  With hepatic encephalopathy

          -  Informed consent signed by their families

        Exclusion Criteria:

          -  Portal bypass surgery

          -  Cancer of any localization

          -  Known malignancy and other severe diseases which shorten life expectancy &lt; 6 months

          -  Psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Mendieta Zerón, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Materno-Perinatal Hospital of the State of Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camilo Rios Castañeda, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Neurology and Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mónica Rodríguez Rodríguez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital &quot;Dr. Darío Fernández Fierro&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital &quot;Dr. Darío Fernández Fierro&quot;</name>
      <address>
        <city>Mexico</city>
        <state>D.f.</state>
        <zip>03900</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <results_first_submitted>January 5, 2009</results_first_submitted>
  <results_first_submitted_qc>August 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2009</results_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <name_title>Hugo Mendieta Zerón</name_title>
    <organization>Materno-Perinatal Hospital of the State of Mexico</organization>
  </responsible_party>
  <keyword>hepatic encephalopathy</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>manganese</keyword>
  <keyword>mortality</keyword>
  <keyword>prognosis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Manganese</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Encephalopathic patients admitted at the Department of Internal Medicine of the General Hospital &quot;Dr. Darío Fernández Fierro&quot; after being stabilized at the Emergency Room</recruitment_details>
      <pre_assignment_details>They were consecutive patients males or females aged &gt; 18 years, with hepatic encephalopathy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Females</title>
          <description>Brain death</description>
        </group>
        <group group_id="P2">
          <title>Males</title>
          <description>Brain death</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Females</title>
          <description>Brain death</description>
        </group>
        <group group_id="B2">
          <title>Males</title>
          <description>Brain death</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.33" spread="3.05"/>
                    <measurement group_id="B2" value="56.66" spread="6.65"/>
                    <measurement group_id="B3" value="54.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="0"/>
                    <measurement group_id="B2" value="72.5" spread="3.53"/>
                    <measurement group_id="B3" value="70.66" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="7.74"/>
                    <measurement group_id="B2" value="63" spread="10.02"/>
                    <measurement group_id="B3" value="59.88" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline blood hemoglobin</title>
          <description>Blood samples when arriving at the Emergency Room were used to measure hemoglobin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.52" spread="1.57"/>
                    <measurement group_id="B2" value="12.14" spread="1.77"/>
                    <measurement group_id="B3" value="11.86" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood levels of manganese</title>
          <description>Blood levels of manganese in patients with encephalopathy when arriving at the Emergency Room</description>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.75" spread="9.47"/>
                    <measurement group_id="B2" value="18.5" spread="10.22"/>
                    <measurement group_id="B3" value="23.05" spread="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Evolution</title>
        <description>Number of participants who died versus those who remained alive after 6 months of follow up since the first entrance at the Emergency Room</description>
        <time_frame>six months</time_frame>
        <population>We made a clinical follow up from nine encephalopathic patients. After six months we studied the differences in Mn, hemoglobin, etc., between those patients still alive and those who died.</population>
        <group_list>
          <group group_id="O1">
            <title>Females</title>
            <description>Brain death</description>
          </group>
          <group group_id="O2">
            <title>Males</title>
            <description>Brain death</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Evolution</title>
          <description>Number of participants who died versus those who remained alive after 6 months of follow up since the first entrance at the Emergency Room</description>
          <population>We made a clinical follow up from nine encephalopathic patients. After six months we studied the differences in Mn, hemoglobin, etc., between those patients still alive and those who died.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Still alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Clinical evolution was reported as percentage (still alive or death after six months of follow up).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5</dispersion_value>
            <estimate_desc>The difference is between the percentage of deaths (males versus females) after six months in the patients with hepatic encephalophathy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Manganese Levels</title>
        <description>From encephalopathic patients, we took individual blood samples, analyzed in the biochemistry laboratory at the National Institute of Neurology and Neurosurgery, Mexico, City, with a graphite furnace atomic absorption spectrometer, according to the technique reported by Pleban.</description>
        <time_frame>Up to six months we followed the recruited patients to determine who were still alive</time_frame>
        <population>All patients attended at the Internal Medicine Service with Hepatic Encephalopathy were included. The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Females</title>
            <description>Brain death</description>
          </group>
          <group group_id="O2">
            <title>Males</title>
            <description>Brain death</description>
          </group>
        </group_list>
        <measure>
          <title>Manganese Levels</title>
          <description>From encephalopathic patients, we took individual blood samples, analyzed in the biochemistry laboratory at the National Institute of Neurology and Neurosurgery, Mexico, City, with a graphite furnace atomic absorption spectrometer, according to the technique reported by Pleban.</description>
          <population>All patients attended at the Internal Medicine Service with Hepatic Encephalopathy were included. The analysis was per protocol.</population>
          <units>μg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.75" spread="9.4"/>
                    <measurement group_id="O2" value="18.5" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Laboratory results were expressed in means and standard deviations. Between group comparisons (female versus male values) were made with the Mann-Whitney U test using the Statistical Package for Social Sciences (SPSS) program version 10 (SPSS Inc., North Carolina, USA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The difference is between manganese levels of women minus manganese levels of men.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Females</title>
          <description>Brain death</description>
        </group>
        <group group_id="E2">
          <title>Males</title>
          <description>Brain death</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Hugo Mendieta Zerón</name_or_title>
      <organization>Materno-Perinatal Hospital of the State of Mexico</organization>
      <phone>+52-722-2176605</phone>
      <email>mezh_74@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

